YZG-331


YZG-331, also known as N6-adenosine, is an adenosine receptor agonist which is or was under investigation for the potential treatment of insomnia.

Pharmacology

The drug appears to act through the adenosine A1 and A2A receptors. It produces sedative and hypnotic effects and hypolocomotion in animals. The drug is orally active and crosses the blood–brain barrier, although its intestinal absorption and central permeability may be reduced by its P-glycoprotein substrate activity. It is a synthetic derivative of adenosine and of N6-(4-hydroxybenzyl)adenine riboside. The latter compound is found in the traditional Chinese medicinal herb Gastrodia elata.

Development

YZG-331 was first described in the scientific literature by at least 2014. As of 2025, it has reached the preclinical research stage of development.